{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T19:38:31Z","timestamp":1794685111388,"version":"4.9.1"},"reference-count":33,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,10,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The main objective of this study was to investigate whether patients with chronic myeloid leukemia (CML) in treatment with long-term therapy imatinib have a different health-related quality-of-life (HRQOL) profile compared with the general population. In total, 448 CML patients were enrolled, and the SF-36 Health Survey was used to compare generic HRQOL profiles. Symptoms were also assessed. HRQOL comparisons were adjusted for key possible confounders. The median age of patients was 57 years and the median time of imatinib treatment was 5 years (range 3-9 years). The largest HRQOL differences were found in younger patients. In particular, patients aged between 18 and 39 years had marked impairments in role limitations because of physical and emotional problems, respectively: \u221222.6 (P &lt; .001), \u221222.3 (P &lt; .001). Patients with CML age 60 or older had a HRQOL profile very similar to that reported by the general population. Women had a worse profile than men when each were compared with their peers in the general population. Fatigue was the most frequently reported symptom. The HRQOL of CML patients is comparable with that of population norms in many areas, however, younger and female patients seem to report the major limitations.<\/jats:p>","DOI":"10.1182\/blood-2011-04-347575","type":"journal-article","created":{"date-parts":[[2011,7,13]],"date-time":"2011-07-13T01:56:36Z","timestamp":1310522196000},"page":"4554-4560","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":227,"title":["Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population"],"prefix":"10.1182","volume":"118","author":[{"given":"Fabio","family":"Efficace","sequence":"first","affiliation":[{"name":"Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Baccarani","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Breccia","sequence":"additional","affiliation":[{"name":"Department of Biotechnologies and Hematology, University of Rome Sapienza, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[{"name":"Department of Biotechnologies and Hematology, University of Rome Sapienza, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianantonio","family":"Rosti","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cottone","sequence":"additional","affiliation":[{"name":"Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio Lambertenghi","family":"Deliliers","sequence":"additional","affiliation":[{"name":"Department of Hematology, Istituto Di Recovero e Cura a Carattere Scientifico Ospedale Maggiore Policlinico, Milan, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Barat\u00e8","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Pisa, Pisa, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella Russo","family":"Rossi","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Bari, Bari, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fioritoni","sequence":"additional","affiliation":[{"name":"Hematology, Local Health Unit of Pescara, Pescara, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigia","family":"Luciano","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Naples Federico II, Naples, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamante","family":"Turri","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Cervello, Palermo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Martino","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ospedali Riuniti, Reggio Calabria, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Ferrarotto, Catania, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Dabusti","sequence":"additional","affiliation":[{"name":"Department of Hematology, Arcispedale Sant'Anna, Ferrara, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micaela","family":"Bergamaschi","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Genova, Clinica Ematologica S. Martino Hospital, Genova, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Leoni","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hospital Torrette, Ancona, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Pina","family":"Simula","sequence":"additional","affiliation":[{"name":"Ospedale Oncologico di Riferimento Regionale Armando Busiinco, Struttura Complessa di Ematologia e Centro Trapianti, Cagliari, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano","family":"Levato","sequence":"additional","affiliation":[{"name":"Department of Hematology, Azienda Ospedaliera Pugliese Ciaccio, Catanzaro, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Ulisciani","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Turin, Orbassano, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dino","family":"Veneri","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Verona, Verona, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Sica","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Rome Cattolica S. Cuore, Rome, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Vignetti","sequence":"additional","affiliation":[{"name":"Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Mandelli","sequence":"additional","affiliation":[{"name":"Italian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for GIMEMA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2019111807372259000_B1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1200\/JCO.2010.31.3619","article-title":"Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.","volume":"29","author":"Cortes","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111807372259000_B2","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"22","key":"2019111807372259000_B3","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract].","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"issue":"11","key":"2019111807372259000_B4","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.2003.12.154","article-title":"Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.","volume":"21","author":"Hahn","year":"2003","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111807372259000_B5","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.3109\/10428194.2011.560310","article-title":"Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia.","volume":"52","author":"Aziz","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"2019111807372259000_B6","article-title":"Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes [published online ahead of print March 22, 2011].","author":"Efficace","journal-title":"Critic Rev Oncol Hematol"},{"issue":"4","key":"2019111807372259000_B7","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cncr.25648","article-title":"Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: definitions and clinical implications.","volume":"117","author":"Pinilla-Ibarz","year":"2011","journal-title":"Cancer"},{"key":"2019111807372259000_B8","first-page":"241","article-title":"Evaluating quality of life in cancer survivors.","volume-title":"Outcomes Assessment in Cancer: Measures, Methods and Applications","author":"Zebrack","year":"2005"},{"issue":"6","key":"2019111807372259000_B9","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"issue":"11","key":"2019111807372259000_B10","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0895-4356(98)00094-8","article-title":"The Italian SF-36 Health Survey: translation, validation and norming.","volume":"51","author":"Apolone","year":"1998","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"2019111807372259000_B11","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1023\/A:1008264412398","article-title":"Evaluation of the EORTC QLQ-C30 questionnaire: a comparison with SF-36 Health Survey in a cohort of Italian long-survival cancer patients.","volume":"9","author":"Apolone","year":"1998","journal-title":"Ann Oncol"},{"key":"2019111807372259000_B12","article-title":"Questionario sullo stato di salute SF-36. Manuale d'uso e guida all'interpretazione dei risultati Versione Italiana.","author":"Apolone","year":"1997"},{"issue":"9","key":"2019111807372259000_B13","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/S0959-8049(98)00136-1","article-title":"Using reference data on quality of life\u2013the importance of adjusting for age and gender, exemplified by the EORTC QLQ-C30 (+3).","volume":"34","author":"Hjermstad","year":"1998","journal-title":"Eur J Cancer"},{"issue":"8","key":"2019111807372259000_B14","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s11136-010-9673-x","article-title":"Gender differences in health-related quality-of-life are partly explained by sociodemographic and socioeconomic variation between adult men and women in the US: evidence from four US nationally representative data sets.","volume":"19","author":"Cherepanov","year":"2010","journal-title":"Qual Life Res"},{"issue":"8","key":"2019111807372259000_B15","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.jclinepi.2007.08.015","article-title":"The relationship between overall quality of life and its subdimensions was influenced by culture: analysis of an international database.","volume":"61","author":"Scott","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"S2","key":"2019111807372259000_B16","first-page":"189","article-title":"Development and feasibility of a patient-reported symptom checklist for chronic myeloid leukemia patients [abstract].","volume":"95","author":"Efficace","year":"2010","journal-title":"Haematologica"},{"issue":"5","key":"2019111807372259000_B17","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.","volume":"85","author":"Aaronson","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"2019111807372259000_B18","volume-title":"SF-36 Health Survey: Manual and Interpretation Guide","author":"Ware","year":"1993"},{"issue":"1","key":"2019111807372259000_B19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects.","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"issue":"12","key":"2019111807372259000_B20","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/jnci\/djp123","article-title":"Impact of cancer on health-related quality of life of older Americans.","volume":"101","author":"Reeve","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"23","key":"2019111807372259000_B21","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.1200\/JCO.2004.02.018","article-title":"Quality of life in patients with colorectal cancer 1 year after diagnosis compared with the general population: a population-based study.","volume":"22","author":"Arndt","year":"2004","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111807372259000_B22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/009286150303700105","article-title":"Practical guidelines for assessing the clinical significance of health-related quality of life changes within clinical trials.","volume":"37","author":"Sloan","year":"2003","journal-title":"Drug Inf J"},{"issue":"10","key":"2019111807372259000_B23","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.3899\/jrheum.090193","article-title":"The minimally important difference for patient reported outcomes in systemic lupus erythematosus including the HAQ-DI, pain, fatigue, and SF-36.","volume":"36","author":"Colangelo","year":"2009","journal-title":"J Rheumatol"},{"issue":"3","key":"2019111807372259000_B24","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3899\/jrheum.090375","article-title":"The minimally important difference in clinical practice for patient-centered outcomes including health assessment questionnaire, fatigue, pain, sleep, global visual analog scale, and SF-36 in scleroderma.","volume":"37","author":"Canadian Scleroderma Research Group","year":"2010","journal-title":"J Rheumatol"},{"issue":"2","key":"2019111807372259000_B25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-0609.2009.01250.x","article-title":"Health related quality of life in a nationally representative sample of haematological patients.","volume":"83","author":"Johnsen","year":"2009","journal-title":"Eur J Haematol"},{"issue":"9","key":"2019111807372259000_B26","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1200\/JCO.2002.06.077","article-title":"Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation.","volume":"20","author":"Kiss","year":"2002","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111807372259000_B27","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cncr.22581","article-title":"Quality of life among long-term non-Hodgkin lymphoma survivors: a population-based study.","volume":"109","author":"Mols","year":"2007","journal-title":"Cancer"},{"issue":"19","key":"2019111807372259000_B28","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1200\/JCO.2005.03.343","article-title":"Quality of life of long-term survivors of breast cancer and lymphoma treated with standard-dose chemotherapy or local therapy.","volume":"23","author":"Ahles","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"2019111807372259000_B29","doi-asserted-by":"crossref","first-page":"4408","DOI":"10.1182\/blood-2003-10-3605","article-title":"Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups.","volume":"103","author":"Kluin-Nelemans","year":"2004","journal-title":"Blood"},{"issue":"5","key":"2019111807372259000_B30","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/00002820-199910000-00002","article-title":"Quality of life in patients with chronic myeloid leukemia after unrelated donor bone marrow transplantation.","volume":"22","author":"Molassiotis","year":"1999","journal-title":"Cancer Nurs"},{"issue":"1","key":"2019111807372259000_B31","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1176\/appi.psy.46.1.34","article-title":"Psychosocial function after hematopoietic stem cell transplantation.","volume":"46","author":"Chang","year":"2005","journal-title":"Psychosomatics"},{"issue":"14","key":"2019111807372259000_B32","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.","volume":"28","author":"Marin","year":"2010","journal-title":"J Clin Oncol"},{"issue":"32","key":"2019111807372259000_B33","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1200\/JCO.2007.11.3803","article-title":"Patient-reported outcomes supporting anticancer product approvals.","volume":"25","author":"Rock","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/17\/4554\/1462950\/zh804311004554.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/17\/4554\/1462950\/zh804311004554.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T07:45:30Z","timestamp":1574063130000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/17\/4554\/29025\/Healthrelated-quality-of-life-in-chronic-myeloid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,27]]},"references-count":33,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2011,10,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-04-347575","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,27]]}}}